Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion

(Immunity 55, 1067–1081.e1–e8; June 14, 2022) While preparing the final version of our study for publication, three inaccuracies were incorporated into the text. Firstly, we erred on using the term “synthase” to describe the biological function of LARS2. LARS2 is a “synthetase” due to its enzymatic activity as a ligase. Secondly, in highlight #3, we inadvertently carried over a dash symbol when typing the term NAD+-. The dash symbol has now been removed. Finally, in the subheading “Coculture of B- and T-cells” located in the STAR Methods, we erroneously indicated that 5∗105 B cells were placed in each well. The correct number of cells is 1∗105 B cells. These errors have been corrected, and the authors apologize for any confusion we may have caused. Leucine-tRNA-synthetase-2-expressing B cells contribute to colorectal cancer immunoevasionWang et al.ImmunityJune 3, 2022In BriefImmunoregulatory B cells impede antitumor immunity through unknown features and mechanisms. Wang et al. discover LARS B subset with TGF-β1 dominant features in progressive CRC and propose a leucine-dieting scheme, limiting LARS B cells by targeting mitochondrial NAD+ regeneration. Full-Text PDF